Added to YB: 2026-06-04
Pitch date: 2026-06-02
ABVX [bullish]
ABIVAX Société Anonyme
+8.53%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Market Cap
EUR 5.0B
Pitch Price
EUR 65.65
Price Target
N/A
Dividend
N/A
EV/EBITDA
-18.08
P/E
-13.95
EV/Sales
929.14
Sector
Biotechnology
Category
special_situation
Abivax (ABVX France): crazy share price action on positive data
ABVX (update): Phase III ABTECT in ulcerative colitis hit primary endpoint—~50% clinical remission (25mg/50mg) vs ~10% placebo at 44wks, all secondary endpoints met. Differentiated miR-124 once-daily oral, stable safety. Stock -25% on cancer cases (monitors saw no causal link); FDA review overhang looms. Author sees strengthened case, possible sale catalyst.
Read full article (2 min)